Overview

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Status:
Completed
Trial end date:
2017-08-02
Target enrollment:
Participant gender:
Summary
Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
Phase:
Phase 1
Details
Lead Sponsor:
Spyryx Biosciences, Inc.
Treatments:
Pharmaceutical Solutions